Abstract: Control circuits for generating output enable signals are disclosed. In one aspect, a control circuit is provided that employs combinatorial logic to generate an output enable signal that meets timing constraints using a standard clock signal, a feedback clock signal based on the standard clock signal, and a single data rate (SDR) data output stream. The control circuit includes a double data rate (DDR) conversion circuit configured to generate a DDR output stream based on a received SDR output stream. The control circuit includes an output enable circuit configured to receive the standard clock signal, feedback clock signal, and DDR output stream, and to generate the output enable signal that is asserted and de-asserted according to the defined timing constraints. The control circuit is configured to generate an accurately timed output enable signal without the need for a fast clock signal in addition to the standard clock signal.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided. The compounds are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Pharmaceutical compositions comprised of one or more compounds of formula (I) are also provided.

Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, and R5 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract: The present embodiments disclose a device including a module for sampling, separating and enriching a detected object, an exhaled breath condensates (EBCs) detection module and a combined volatile organic compounds (VOCs) detection module. The sampling module is connected with the EBCs detection module via a syringe pump for sample injection and is connected with the combined VOCs detection module by a capillary separation column. EBCs and VOCs in human exhaled breath are simultaneously sampled, separated and condensed; the heavy metal ions, cell factors, etc. in the collected EBCs are detected with a light addressable potentiometric sensor (LAPS); the condensed VOCs can be quantitatively detected by the combined VOCs detection module with a high sensitivity; and a heating rod and a platinum resistor can be conveniently replaced because a separated outlet heating piece is designed in the combined VOCs detection module.

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

Abstract: Cancelling a delay in a comparator of an RC oscillator configured to generate a clock pulse, including: selectively coupling a plurality of current sources to a first capacitor, a second capacitor, and a resistor, wherein the plurality of current source charge and discharge the first capacitor and the second capacitor, and charge the resistor; charging the first capacitor at a higher rate during a first phase of the clock pulse than a second phase of the clock pulse, and charging the second capacitor at a higher rate during a third phase of the clock pulse than a fourth phase of the clock pulse; and generating the clock pulse by enabling the comparator to compare a voltage on the first or second capacitor with a voltage on the resistor.

Abstract: Methods and apparatuses are provided for displaying a browser navigation page. The disclosed methods and apparatuses may generate a browser navigation page that have one or more icons displayed with preset areas at irregular positions in the browser navigation page. The disclosed methods and apparatuses may generate a browser navigation page in which the areas of the icons may be adjusted according to click counts of the icons.

Abstract: The present invention provides for compounds of formula (I). wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Abstract: A dual-stage hybrid inflator and triggering a method thereof are provided. The dual-stage hybrid inflator includes a main casing, a central pipe, and a disc set, a first propellant chamber assembly, a second propellant chamber assembly, a pressurized gas, a first igniter assembly, a second igniter assembly and an exhaust hood. The main casing includes a bottom housing and an upper housing. The central pipe is fixed with the bottom housing and passed through the upper housing. A convective hole is disposed on the central pipe. The disc set, which is used to prevent the gas escaping from the main casing, is disposed on the top of the central pipe. The doublet propellant chamber, which is filled with different dosage of propellant, is initiated by the igniters disposed thereon in order to generate various degrees of gas depended on various degrees of collision.

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

Abstract: Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein are disclosed.

Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract: A valve assembly including a valve body having a first pressure chamber and a second pressure chamber, the pressure of the first pressure chamber being lower than that of the second pressure chamber. The pressure of the second pressure chamber is discharged to the first pressure chamber in response to the change of the pressure of the first pressure chamber. A blocking device is arranged between the first pressure chamber and the second pressure chamber. A valve stem is arranged in the valve body with one end movably contacting the blocking device. A diaphragm is connected to the valve stem and is arranged adjacent to or above the first pressure chamber. When the pressure of the first pressure chamber is changed, the diaphragm forces the valve stem to move by sensing the pressure change of the first pressure chamber.

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, and R5 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract: A driver circuit includes detectors responsive to the operating region that a driven switch is operating in. The driver circuit is operative to drive the gate of the driven switch at a speed responsive to the output of the detectors.

Abstract: Exemplary embodiments are directed to systems, devices, methods, and computer-readable media for reducing static and dynamic power consumption of a charge pump. In one embodiment, a device may include a plurality of switches, each switch of the plurality having a gate coupled to a dedicated driver of a plurality of drivers. The device may further include at least one clamp switch coupled to at least one driver of the plurality of drivers and configured to adjust a rail voltage of the at least one driver if an input voltage is greater than a threshold voltage. In another embodiment, the device may include a plurality of multiplexers, each multiplexer of the plurality of multiplexers coupled to a portion of an associated switch of the plurality of switches and configured to disable the portion of the associated switch if a clock frequency of the charge pump is below a threshold frequency.

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.